Cmed, the leading clinical research organisation and technology development company, has entered into a partnership agreement with Tessella, the information technology and consulting services coompany selected by R&D, science and engineering leaders for business-critical assignments. Under the terms of the agreement, Tessella and Cmed will ensure interoperability of Timaeus, the Intelligent Data Acquisition and Management system (iDAM) with Tessella FATES™, Tessella’s fixed and adaptive trial execution system.

“With Timaeus, organisations have the ability to acquire, manage and report data in near real-time. This is particularly important for adaptive trials because it minimises the delay in the availability of response data and therefore adaptation of the trial,” said Tom Parke, head of clinical technologies at Tessella. Parke added, “The interoperability of two best of breed clinical trial products represents an important step in removing the operational complexity associated with adaptive clinical trials.”

Richard Young, Director of Business Development at Cmed said: “Tessella and Cmed have been collaborating for some time; not least of all through our Adaptive Trial Design symposium (February 2009). By entering into a partnership this will reinforcee our capabilities, and provide unparalleled solutions for adaptive designs.” Young continues: “Tessella bring huge experience in the design, simulation and execution of adaptive trial designs and the interoperability of Tessella FATES and Timeaus enables bio-tech and pharma companies the ability to leverage this knowhow.”